Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on pioneering therapies for allergic and inflammatory diseases, today revealed two significant advancements in the development of its proprietary antisense oligonucleotide (ASO) cancer-fighting drug candidate, HT-KIT.
The company has filed amended claims with the U.S. Patent and Trademark Office to further strengthen the intellectual property protection for HT-KIT. This ASO technology targets MS4A6A and FcεRIβ—genes that are associated with allergic inflammation and mast cell-related diseases. The updated claims enhance HT-KIT’s intellectual property portfolio, reinforcing its position as a unique therapeutic platform with the potential to treat conditions like anaphylaxis, mastocytosis, and allergic asthma.
In addition, Hoth Therapeutics has initiated a Good Laboratory Practice (GLP)-compliant 4-week intravenous toxicity study with a 14-day recovery period in C57BL/6 mice. Conducted in partnership with OnTargetx R&D Inc. and ITR Laboratories, this preclinical study aims to assess the safety profile of HT-KIT in preparation for future regulatory filings. The study will include multiple dose groups, comprehensive pathology assessments, and pharmacokinetic profiling.
Next Steps in Development
Hoth Therapeutics remains dedicated to advancing HT-KIT toward clinical evaluation. The company is conducting additional preclinical studies to further validate the drug’s efficacy and safety profile, and plans to begin regulatory discussions for first-in-human trials soon.
For more information on Hoth Therapeutics and its innovative pipeline, visit www.hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company committed to developing groundbreaking treatments aimed at improving patient quality of life. We focus on early-stage pharmaceutical research and development, progressing drugs from the bench to preclinical and clinical testing. By partnering with a team of scientists, clinicians, and key opinion leaders, we aim to discover therapeutics that hold the potential for breakthroughs and offer diverse treatment options. To learn more, visit https://ir.hoththerapeutics.com.